Increasing E3 activity of TRIM21 in macrophages may help to reducing the level of IRF5 in some but not all patients, as it will be ineffective against the isoform v2 linked to overexpression of IRF5 and to susceptibility to SLE 52. Here, IRF5 is linked to systemic lupus erythematosus.